Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Papatheodoridis

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
JHEP Reports : Innovation in Hepatology|October 27, 2025
Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in patients with chronic HBV with advanced fibrosisLesley A Patmore, Lilian Y Liang, George Papatheodoridis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
JHEP Reports : Innovation in Hepatology|May 20, 2026
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohortSabela Lens, Habiba Kamal, Arno Furquim d'Almeida, et al.
JHEP Reports : Innovation in Hepatology|July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort studyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Gastroenterology|September 28, 2023
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Journal of Viral Hepatitis|June 20, 2026
HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis DDimitra Lakiotaki, Margarita Papatheodoridi, Vasilios Sevastianos, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 8, 2023
HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patientsGeorge Papatheodoridis, Konstantinos Mimidis, Spilios Manolakopoulos, et al.
Contemporary Clinical Trials|October 12, 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver diseaseTimothy Hardy, Kristy Wonders, Ramy Younes, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
JHEP Reports : Innovation in Hepatology|October 27, 2025
Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in patients with chronic HBV with advanced fibrosisLesley A Patmore, Lilian Y Liang, George Papatheodoridis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
JHEP Reports : Innovation in Hepatology|May 20, 2026
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohortSabela Lens, Habiba Kamal, Arno Furquim d'Almeida, et al.
JHEP Reports : Innovation in Hepatology|July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort studyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Gastroenterology|September 28, 2023
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Journal of Viral Hepatitis|June 20, 2026
HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis DDimitra Lakiotaki, Margarita Papatheodoridi, Vasilios Sevastianos, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 8, 2023
HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patientsGeorge Papatheodoridis, Konstantinos Mimidis, Spilios Manolakopoulos, et al.
Contemporary Clinical Trials|October 12, 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver diseaseTimothy Hardy, Kristy Wonders, Ramy Younes, et al.
Pageof 14